Comment on ‘Long-term effectiveness of bimekizumab in plaque psoriasis: 2-year drug survival from a real-life multicenter Italian study’

Clicks: 24
ID: 321170
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #89 of 245 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This comment highlights that drug survival is a valuable real-world outcome but should not be interpreted as a direct surrogate of biological effectiveness, as it is influenced by multiple clinical and non-clinical factors. It also emphasizes the importance of appropriate competing-risk analyses and patient-centred outcomes to better evaluate the long-term effectiveness of bimekizumab in psoriasis.
Reference Key
openalex_W7168348119 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ercan Yılmaz, Nezihe Koker Özer, Erdem Topal
Are you one of these authors? Claim your profile
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag297
URL
https://doi.org/10.1093/ced/llag297
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.